Data annotation job

Biotech Investment Analyst, Drug Asset & Company Assessment

Mercor · Posted 4 weeks ago

$120 to $200/hrRemote (US)Part time
  • AI evaluation
  • Healthcare
  • Finance

About this role

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work, creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.

Responsibilities

  • Create and critique rubrics that analyze commercial drugs and drug-development programs
  • Provide overall company and asset assessment, mechanism, clinical data, competitive position, and value drivers
  • Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
  • Apply your assessment across the pilot's set of companies (~5 to 10)

Requirements

  • US-based biotech / healthcare investment analyst with a specialist-fund background
  • Familiarity with biotech/pharma development programs
  • Able to assess a drug asset and the company behind it end-to-end
  • 5+ years evaluating biotech/pharma companies or assets

Engagement Details

  • Duration: Approximately 10 to 20 hours over a 1 to 2 week pilot
  • Remote, US-based

Why Participate

  • Help improve expert AI evaluation of drugs and drug-development programs
  • Recurring engagement for strong contributors

This listing is aggregated by DataAnnotationJobs.org. Applications are processed by Mercor, not by this site.

Mercor is an AI-native talent marketplace connecting vetted domain experts such as doctors, lawyers, and engineers directly with frontier AI labs for RLHF, evaluation, and specialized training data at massive scale. See all Mercor jobs.

Apply for this role

Your details first, then a short screening test. Both are read as part of your application and go to Mercor, and we will tell you when similar roles appear.

Related data annotation jobs